此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Single-Arm, Multicenter, Phase II Study of Candonilimab Combined With Fruquintinib With or Without Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Therapy Containing a PD-(L)1 Inhibitor

This is a Phase II Study of Candonilimab Combined with Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

研究概览

详细说明

This study will enroll patients with advanced gastric or gastroesophageal junction adenocarcinoma who experienced disease progression on first-line PD-(L)1 inhibitor-containing therapy. Eligible patients will receive candonilimab combined with fruquintinib and paclitaxel albumin-bound as second-line treatment, and the combination therapy will be continued until disease progression, intolerable toxicity, withdrawal of informed consent, or achievement of the maximum treatment duration specified in the study protocol.

研究类型

介入性

注册 (估计的)

59

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Hubei
      • Wuhan、Hubei、中国、430030
        • 招聘中
        • Union Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Have a full understanding of the study and voluntarily sign the informed consent form;

  2. Aged 18 to 75 years (inclusive);

  3. Pathologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma;

  4. Prior failure of first-line standard chemotherapy;

  5. HER2-negative status;

  6. ECOG performance status of 0 to 2;

  7. Expected survival of ≥3 months;

  8. Presence of at least one measurable lesion, defined as:

    • Longest diameter ≥10 mm as assessed by spiral CT scan;
    • Diameter ≥20 mm as assessed by conventional CT scan(per Response Evaluation Criteria in Solid Tumors, RECIST version 1.1);
  9. Major organ function meeting the following requirements (use of any blood products or hematopoietic growth factors within 14 days prior to enrollment is not permitted):

    • Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;
    • Platelet (PLT) count ≥100 × 10⁹/L;
    • Hemoglobin (Hb) ≥90 g/L;
    • Total bilirubin (TBIL) <1.5 × upper limit of normal (ULN);
    • Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <1.5 × ULN (or <3 × ULN for patients with liver metastases);
    • Serum creatinine <1.5 × ULN;
    • Creatinine clearance rate (CCr) ≥50 ml/min;
  10. Men and women of childbearing potential must agree to use effective contraceptive measures;

  11. Willingness to provide sufficient tumor tissue samples for PD-L1 expression testing.

Exclusion Criteria:

Patients will be excluded from this study if they meet any of the following criteria:

  1. Inability to comply with the study protocol or study procedures;
  2. Prior treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors or prior use of immune checkpoint inhibitors;
  3. History of other malignant tumors within the past 5 years, except for basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix after curative resection;
  4. Presence of central nervous system (CNS) metastases or history of brain metastases prior to enrollment;
  5. Diagnosis of autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;
  6. Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
  7. Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or paracentesis as judged by the investigator);
  8. Severe cardiovascular diseases occurring within 6 months prior to the initiation of study treatment, including unstable angina pectoris or myocardial infarction; cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting (CABG) within 6 months prior to enrollment; congestive heart failure (CHF) with New York Heart Association (NYHA) classification > Grade 2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) < 50%;
  9. Subjects with known hypersensitivity to the study drugs or any of their excipients;
  10. Participation in other clinical trials of unapproved or unmarketed drugs in China and receipt of the corresponding investigational drug treatment within 4 weeks prior to enrollment;
  11. International Normalized Ratio (INR) > 1.5 or activated partial thromboplastin time (APTT) > 1.5 × upper limit of normal (ULN);
  12. Electrolyte abnormalities deemed clinically significant by the investigator;
  13. Uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) that cannot be controlled with medications prior to enrollment;
  14. Poorly controlled diabetes mellitus prior to enrollment (fasting blood glucose concentration ≥ Common Terminology Criteria for Adverse Events [CTCAE] Grade 2 after standard treatment);
  15. Any disease or condition that may affect drug absorption prior to enrollment, or inability to take fruquintinib orally;
  16. Active peptic ulcers of the stomach and duodenum, ulcerative colitis, or other gastrointestinal diseases; active bleeding from unresected tumors; or other conditions judged by the investigator to potentially cause gastrointestinal bleeding or perforation prior to enrollment;
  17. Active or uncontrolled severe infections (≥ CTCAE v5.0 Grade 2 infections);
  18. Known human immunodeficiency virus (HIV) infection; known history of clinically significant liver disease, including viral hepatitis [subjects known to be hepatitis B virus (HBV) carriers must be excluded if they have active HBV infection, i.e., HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL)];
  19. Unresolved toxicities above CTCAE v5.0 Grade 1 resulting from any prior anticancer treatment, excluding alopecia, lymphopenia, and ≤ Grade 2 neurotoxicity caused by oxaliplatin;
  20. Pregnant females (positive pregnancy test prior to drug administration) or females who are breastfeeding;
  21. Receipt of blood transfusion, blood products, or hematopoietic factors (e.g., albumin, granulocyte colony-stimulating factor [G-CSF]) within 14 days prior to enrollment;
  22. Any other diseases, clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory test abnormalities; conditions judged by the investigator to make the subject unsuitable for study drug administration (e.g., epilepsy requiring treatment), potentially interfere with the interpretation of study results, or place the subject at high risk;
  23. Urinalysis indicating urinary protein ≥ 2+ and 24-hour urinary protein excretion > 1.0 g;
  24. Complications requiring long-term immunosuppressive therapy, or systemic or local use of immunosuppressive corticosteroids (> 10 mg/day prednisone or equivalent therapeutic hormones);
  25. Subjects deemed unsuitable for enrollment in this study by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:candonilimab combined with fruquintinib and paclitaxel albumin-bound

Candonilimab: 10 mg/kg Q3W Fruquintinib: 4 mg orally qd, administered for 2 consecutive weeks followed by 1 week of rest Paclitaxel Albumin-Bound: 130 mg/m² on Day 1 and Day 8 (D1, D8), every 3 weeks, for a total of 6 cycles

Candonilimab: 10 mg/kg every 3 weeks (Q3W) Fruquintinib: 4 mg orally once daily (qd), administered for 2 consecutive weeks followed by 1 week of rest Paclitaxel Albumin-Bound: 130 mg/m² on Day 1 and D

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:from date of randomization until the date of progressive disease or EOT due to any cause, assessed up to 1 year

ORR is defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1 and mRECIST.

from date of randomization until the date of progressive disease or EOT due to any cause, assessed up to 1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年7月19日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年9月27日

首先提交符合 QC 标准的

2026年11月3日

首次发布 (实际的)

2026年11月5日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅